STOCK TITAN

Vanguard disaggregates holdings; IDEXX (NASDAQ: IDXX) shows zero

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

IDEXX Laboratories Inc Schedule 13G/A amendment shows The Vanguard Group reports 0 shares beneficially owned and 0% of common stock. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does the Vanguard Schedule 13G/A for IDXX state?

It states that The Vanguard Group beneficially owns 0 shares and 0% of IDEXX common stock. The filing is an amendment explaining an internal realignment requiring certain subsidiaries to report holdings separately under SEC Release No. 34-39538.

Why did Vanguard file this amended Schedule 13G/A for IDEXX (IDXX)?

Vanguard explains an internal realignment effective January 12, 2026, that disaggregated reporting among subsidiaries. In reliance on SEC Release No. 34-39538, those subsidiaries now report beneficial ownership separately and The Vanguard Group no longer reports aggregated ownership for those holdings.

Does the filing indicate Vanguard will sell or buy IDEXX shares?

The filing only reports ownership levels and internal reporting changes; it records 0 shares beneficially owned. It does not describe any purchase or sale transactions, nor does it state any intended trading activity in IDEXX common stock.

Who signed the Schedule 13G/A amendment for Vanguard regarding IDEXX?

The filing is signed by Ashley Grim, identified as Head of Global Fund Administration. The signature block shows the amendment date as 03/27/2026 and lists Vanguard's Malvern, Pennsylvania principal business address.
IDEXX Laboratories

NASDAQ:IDXX

View IDXX Stock Overview

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

45.65B
79.04M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK